RE: Stockpickers Financial Times31 Jan 2026 11:18
Thanks for sharing the link. The problem with the article and the current broker income forecast for 2026 is that it can’t take into account any potential commercialisation deals for Goliath. If these happen (which I believe they will) then the potential upside in share price is enormous. Anyway below are the key points from the article.
They have Ilika as a HOLD for the following reasons… in their words not mine:
The addressable market for batteries is vast and expanding, particularly in medical technology, defence, household convenience products and robotics.
Prototypes of its latest Goliath battery are being evaluated and tested across a range of industries, and it has signed a 10-year manufacturing licensing deal with US company Cirtec Medical for Stereax.
Investors have to be realistic about the risks — solid state is no ordinary growth story, but in Ilika’s favour is its 20-plus year head start and its business model which allows it to license as well as manufacture its technology. That brings the potential for high-margin revenues, and the ability to scale up fast.
What it has yet to do, though, is successfully commercialise its technology — though it appears to be getting closer. Customers are, however, still at the evaluation stage and Ilika’s sole source of fundraising (other than tapping shareholders) remains government grants.
Although the company expects more of these in the future, there are potential gaps looming.
On top of this, house broker Cavendish has pushed back timelines for its batteries to generate meaningful revenue, slashing its sales target for this year to £1.5mn (from £2.8mn previously) and next year to £2mn (from £6.1mn).
Ilika’s shares aren’t quite a binary bet. A breakthrough in commercialisation could bring huge rewards, but further delays are unlikely to be disastrous. The company will need more funding.